The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced ...
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, ...
The U.S. Food and Drug Administration (FDA) on Thursday expanded the use of GSK's (NYSE:GSK) PD-1-blocking antibody therapy, dostarlimab (Jemperli), for a broader group of patients with endometrial ...
Findings showed in the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved dostarlimab in combination with chemotherapy for certain women with endometrial cancer. The ...
In the overall study population, treatment with dostarlimab-gxly plus chemotherapy reduced the risk of death by 31% vs placebo plus chemotherapy. The Food and Drug Administration (FDA) has accepted ...
The US Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback